Skip to main content

Actualités Leica Biosystems

Updates about Leica Biosystems.

csm_Leica_Biosystems
Published: 8 November 2022

San Diego, CA – November 8, 2022. Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, has acquired Cell IDx, Inc., a leader in multiplexed tissue profiling. Founded in 2012 and headquartered in San Diego, California, Cell IDx provides multiplex…

Digital-Pathology-Connections-Community-Debuts-at-Pathology-Visions-2022
Published: 13 October 2022

Pathologists Can Join the Global Community at PathVisions Booth 214 & Online LAS VEGAS, Nev. (Oct. 13, 2022) – Pathologists from Europe, Japan and the United States today jointly announced the debut of Digital Pathology Connections (DPC), a global community for professionals interested in the…

csm_Leica_Biosystems
Published: 29 July 2022

The company’s latest Advanced Staining Solution, BOND-PRIME, is primarily manufactured in Melbourne, Australia MELBOURNE – Leica Biosystems is pleased to announce that the company was a finalist for the 2022 Victorian Manufacturing Hall of Fame Award for Manufacturer of the Year (Large Business).…

BOND-RX-_-NanoString-Geo-MX-DSP-AUTOMATED-PROFILING-Banner
Published: 1 March 2022

SEATTLE, USA and MELBOURNE, AUSTRALIA. March 1st Leica Biosystems continues to advance its relationship with NanoString Technologies Inc., supporting translational research to build confidence in reproducibility and throughput while minimizing manual steps and reducing hands-on time with the…

csm_Leica_Biosystems
Published: 3 February 2022

Solution enables laboratory managers to optimize their tissue processor workflow. NUSSLOCH, GERMANY, FEB 1, 2022. Leica Biosystems is proud to add a new offering to its dualretort tissue processer portfolio: the HistoCore PEGASUS is now available in North American geographies. Building on more than…

csm_Leica_Biosystems
Published: 31 January 2022

CAMBRIDGE, MASS., JANUARY 31, 2022. Companion diagnostic supports patient identification and enrollment into clinical trials of Leap Therapeutics‘ DKK1 inhibitor, DKN-01 Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (Nasdaq: LPTX), a…